Aim This multicentre observational study was conducted to confirm the observed retrospective findings prospectively in UK clinical practice.

Methods Retrospective data were collected in the 12 months prior to and prospective data for up to 12 months following omalizumab initiation. The primary endpoint was the change in mean daily OCS dosage (reported previously). Secondary endpoints included changes in mean exacerbation frequency (defined as requiring hospital admission or Accident and Emergency (A&E) attendance and/or a course of OCS (dosage increase of at least 10 mg/day for at least 3 days)), healthcare utilisation and missed days in education or at work.

Results 235 patients were enrolled in the study at end December 2013 in 22 UK centres. Data for interim analysis were examined from patients with 12 months of assessment at database lock ($n = 85$, females, 54%, mean ($\pm$ SD) age 44 yr (± 13.2), mean ($\pm$ SD) duration of asthma 26 yr (± 14.0)). At the 16 weeks assessment 74/85 (87%) patients were classified as responders to omalizumab treatment. Comparing the 12 month periods prior to and following initiation of omalizumab, mean total exacerbations decreased by 51% from (mean, $\pm$ SD) 4.25 ± 2.73 to 2.07 ± 2.01 (mean difference 2.18, $p < 0.001$), while mean exacerbations involving hospital visits decreased by 61% from 1.52 ± 2.00 to 0.59 ± 1.25 (difference 0.93, $p < 0.001$). A&E attendances were reduced from 54 to 19 ($p < 0.01$) and inpatient hospitalisations from 85 to 36 ($p < 0.001$). The percentage of average days absent from work or education due to sickness was more than halved in the 12 months pre and post omalizumab initiation reducing from 19.6% to 7.72% ($n = 27$, $p < 0.05$).

Conclusions The data prospectively confirms that omalizumab is associated with significant reduction in exacerbations, healthcare utilisation and societal burden in severe allergic asthma patients as was reported in the retrospective study.

S94

A PROSPECTIVE STUDY INVESTIGATING ORAL CORTICOSTEROID (OCS) USE AND QUALITY OF LIFE IN OMALIZUMAB TREATED SEVERE ALLERGIC ASTHMA PATIENTS – RESULTS FROM AN INTERIM ANALYSIS OF THE APEX II STUDY

¹R Chaudhuri, ²A Menzies-Gow, ³H Khachi, ⁴S Hand, ⁵R Gore, ⁶R Niven. ¹Gartnavel General Hospital, Glasgow, UK; ²Royal Brompton, London, UK; ³London Chest Hospital, London, UK; ⁴Prince Charles Hospital, Merthyr Tydfil, UK; ⁵Lister Hospital, Stevenage, UK; ⁶University Hospital of South Manchester, Manchester, UK

10.1136/thoraxjnl-2014-206260.100

Background A previous retrospective study of UK clinical practice demonstrated that omalizumab reduced OCS burden.

Aim This multi-centre observational study was conducted to confirm the observed retrospective findings prospectively.

Methods Retrospective data were collected in the 12 months prior to omalizumab, while prospective data were collected at 16 weeks, 8 and 12 months following initiation. The primary endpoint was the change in mean daily OCS dose in the 12 months pre and post omalizumab initiation. Secondary endpoints included changes in ACT and AQLQ scores in the 12 months pre and post omalizumab initiation.

Results 235 patients were enrolled by the end December 2013 in 22 UK centres. Data for interim analysis were examined from patients who had 12 months assessment at database lock ($n = 85$, 54% females, mean ($\pm$ SD) age 44 yr (± 13.2), mean ($\pm$ SD) duration of asthma 26 yr (± 14.0)). At the 16 weeks assessment 74/85 (87%) patients were classified as responders to

Abstract S94 Graph 1 Mean AQLQ score pre and post omalizumab initiation - ITT group

omalizumab treatment. At 12 months, mean daily OCS dose decreased by 25% ($n = 85$, $p < 0.001$) from 10.77 mg/day (± 7.87) to 8.08 mg/day (± 8.39) and 55% ($n = 46/84$) of patients stopped OCS. 71% ($n = 60/85$) of patients stopped or reduced OCS by $\geq 20\%$. Comparing the 12 months periods prior to and following initiation of omalizumab, the mean ACT score improved from 9.8 (± 4.8) to 14.2 (± 5.2) ($n = 75$, $p < 0.001$) and the mean AQLQ score improved from 3.1 (± 1.3) to 4.3 (1.46) ($n = 60$, $p < 0.001$) [Graph 1].

Conclusions The data prospectively confirms that omalizumab is associated with statistically and clinically significant reduction in OCS and statistically and clinically significant improvement in asthma symptom control and quality of life.

S95

DOUBLE-BLIND MULTI-CENTRE RANDOMISED CONTROLLED TRIAL OF VITAMIN D₃ SUPPLEMENTATION IN ADULTS WITH INHALED CORTICOSTEROID-TREATED ASTHMA (VIDIAS)

¹AR Martineau, ¹BD MacLaughlin, ¹RL Hooper, ¹NC Barnes, ¹DA Jolliffe, ²AB Choudhury, ³RK Rajakulasingam, ³A Bhowmik, ⁴DE Simcock, ¹J Grigg, ⁵CJ Corrigan, ⁵CM Hawrylowicz, ¹CJ Griffiths. ¹Queen Mary University of London, London, UK; ²Queen's Hospital, Romford, UK; ³Homerton Hospital, London, UK; ⁴Royal London Hospital, London, UK; ⁵King's College London, London, UK

10.1136/thoraxjnl-2014-206260.101

Introduction and objectives Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URI). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. A recent vitamin D trial in adults with asthma reported a trend towards reduced exacerbation risk in the intervention arm as a secondary outcome. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking. We therefore conducted a multi-centre randomised controlled trial of vitamin D₃ supplementation in adults with asthma with co-primary outcomes of severe exacerbation and URI.

Methods Two hundred and fifty adults with inhaled corticosteroid (ICS)-treated asthma were allocated to receive six 2-monthly oral doses of 3 mg vitamin D₃ or placebo over one year. Co-primary outcomes were time to first severe exacerbation and time to first URI. Sub-group analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for thirty-four single nucleotide polymorphisms in eleven vitamin D pathway genes.

Results Participants were allocated to vitamin D₃ vs. placebo in equal numbers; 82% were vitamin D insufficient at baseline. Vitamin D₃ supplementation did not influence time to first severe exacerbation (aHR 1.02, 95% CI 0.69–1.53, *P* = 0.91) or time to first URI (aHR 0.87, 95% CI 0.64–1.16, *P* = 0.34). The influence of vitamin D₃ on co-primary outcomes was not modified by baseline vitamin D status or genotype. Of 16 pre-specified secondary outcomes, only one showed a difference between arms: vitamin D supplementation induced a modest improvement in respiratory quality of life as evidenced by a reduction in mean total score for the St George's Respiratory Questionnaire at 2 months (-3.9 points, *p* = 0.005), 6 months (-3.7 points, *p* = 0.038) and 12 months (-3.3 points, *p* = 0.060).

Conclusions Vitamin D₃ supplementation did not influence time to exacerbation or URI in a population of adults with ICS-treated asthma with a high prevalence of baseline vitamin D insufficiency.

S96

BRONCHIAL THERMOPLASTY REDUCES PERIPHERAL BLOOD EOSINOPHILS IN SEVERE ASTHMA DEMONSTRATING SYSTEMIC EFFECTS OF A LOCALISED THERAPY

DM Ryan, LJ Holmes, G McCumiskey, RD Daly, K Hince, G Tavernier, S Fowler, RM Niven. University Hospital South Manchester, Manchester, UK

10.1136/thoraxjnl-2014-206260.102

Introduction Severe Asthma, characterised by persistent symptoms despite maximal medical therapy, represents 5% of asthma cases. Bronchial Thermoplasty (BT) is a novel therapy, NICE approved for Severe Asthma patients uncontrolled despite step 4/5 of British Guideline on Asthma Management. BT delivers radiofrequency thermal energy to airways distal to the mainstem bronchi, permanently reducing airway smooth muscle mass. It is unknown whether treatment of smooth muscle hypertrophy impacts persistently upon systemic signs of allergic inflammation. Peripheral blood eosinophils (PBEs) are a marker of allergic inflammation in asthma. We asked: does BT modify signs of allergic inflammation as measured by PBEs and if so, does this effect persist over time?

Method A retrospective review of 15 consecutive Severe Asthma cases treated with BT was performed. Serial PBEs measured

Abstract S96 Figure 1

before and up to 1 year after BT were compared. Blood eosinophil levels taken peri-procedure were excluded from analysis due to standard protocol concomitant steroid therapy. For time to first detectable high PBE all available post-BT PBE levels were assessed.

Results 13 patients had PBE data before and after BT, with an average of 9 and 12 serial PBE levels pre and post-BT respectively. Mean PBE 1 year pre-BT was $0.33 \times 10^9/L$ falling to a mean of $0.16 \times 10^9/L$ 1 year post-BT (*p* < 0.05) (see Figure). 9 of 13 patients had a fall in mean PBE, in 2 of 13 levels rose and 1 of 13 mean PBEs were unchanged post-BT. In 6 patients who converted from normal to high PBE post-BT, average time to first high PBE ($>0.4 \times 10^9/L$) was 7 months (range 1–13 months). In 5 patients (38%) PBE remained within normal range persistently post BT.

Conclusion Severe Asthma patients undergoing BT had a significant reduction in average peripheral blood eosinophil levels from baseline. In over 1/3 of cases this effect was persistent 1 year post procedure. These findings support the concept that BT not only reduces asthma-associated smooth muscle hypertrophy but impacts upon systemic markers of allergic inflammation.

Mechanistic insights in acute lung injury

S97

LONG TERM SURVIVAL IN PATIENTS WHO UNDERGO OESOPHAGECTOMY IS LOWER IN PATIENTS WHO DEVELOP POST-OPERATIVE ACUTE RESPIRATORY DISTRESS SYNDROME

¹RCA Dancer, ¹D Parekh, ²GD Perkins, ¹DR Thickett. ¹University of Birmingham, Birmingham, UK; ²University of Warwick, Coventry, UK

10.1136/thoraxjnl-2014-206260.103

Oesophagectomy is a complicated procedure with high risk of complications in the immediate post-operative period. We have previously shown that patients undergoing oesophagectomy have ~ 25% risk of Acute Respiratory Distress Syndrome (ARDS) post op. Post-operative complications have been shown to decrease long term post-operative survival following major surgery.¹We hypothesised that long term survival would be reduced in patients who develop ARDS post oesophagectomy.

We analysed data from 55 patients recruited to the translational sub-study of the BALTI prevention trial. 26 of the 55 patients (47%) died within 2 years of their operation.

Patients who died within two years of their oesophagectomy were more likely to have required ventilation for ARDS during their hospital admission. In addition, patients who survived less than two years were more likely to have developed a surgical complication (e.g. anastomotic leak, wound infection, chyle leak) post-op. There was no difference in age, lung function, BMI or cancer staging. Patients who did not survive more than 2 years post-op were more likely to be smoking at the time of the operation, but there was no difference in pack year smoking history between the two groups.

Perioperative markers of alveolar epithelial damage (PICCO EVLWI and PVPI), and the severity of both local (BAL CRP) and systemic inflammation (IL-17, ICAM-1, and TNFR-1/2) were associated with outcome.

In conclusion, complications during recovery from oesophagectomy have an adverse effect on the chances of long term survival. Development of strategies to reduce post-operative morbidity may improve long term outcomes.